Johnson & Johnson to start late-stage coronavirus vaccine trial in September with up to 60,000 people – IOTW Report

Johnson & Johnson to start late-stage coronavirus vaccine trial in September with up to 60,000 people

CNBC-

Johnson & Johnson plans to begin what would be the largest, late-stage trial testing a potential coronavirus vaccine in September, the company confirmed Thursday.

The phase three trial would enroll up to 60,000 healthy people ages 18 and older across nearly 180 locations in the U.S. and other countries, according to a J&J spokesman and ClinicalTrials.gov. 

Participants will be randomly selected to receive a dose of the potential vaccine or a placebo, according to details of the trial, which will determine whether the vaccine is safe and effective. They will be followed by researchers for more than two years.

“Our Phase 3 program is intended to be as robust as possible, could include up to 60,000 participants and will be conducted in places with high incidence rates,” J&J spokesman Jake Sargent said in a statement to CNBC. “We are using epidemiology and modeling data to predict and plan where our studies should take place and expect that to be finalized soon.” more

11 Comments on Johnson & Johnson to start late-stage coronavirus vaccine trial in September with up to 60,000 people

  1. CNN & The Democrats will not like this.

    They don’t like people outside & living their lives, only locked in the basement watching CNN.

    7
  2. interesting ferret experiment several yrs ago on rna based vaccinations against respiratory viruses. results looked great…ferrets generated loads of antibodies. but when ferrets were exposed to virus, every single one died. all those lovely antibodies generated very active cytokine storms by their immune systems and they all died of organ failure.

    4

Comments are closed.